VisualCV

Interim Chief Financial Officer – December 2007 to June 2008

Recommended by PPI investor and selected to re-engineer decision support and cost accounting systems and complete the 2008 budget amid a critical strategic inflection point resulting from changing service mix, contribution margins, and market penetration.  Report to the CEO.

Pioneered the cost model boasting >95% accuracy against actual costs, leading to 2008 product re-pricing, providing the basis for the 2008 budget and 5-year financial models, and completely transforming the company's business model.

Rebuilt financial and productivity models that fostered multi-dimensional analysis and understanding of historic and projected financial results and enabled the management team to prioritize and focus on key strategic decision points with a product-by-product roadmap to profitability.

Created the reliable zero-based financial model and 2008 budget, which facilitated the May 2008 corporate restructuring; and built the sustainable business model which influenced existing investors to capitalize the restructuring plan.

Halted the pattern of inaccurate and untimely financial statement production, improving the closing of accurate statements to 15 days while simultaneously reducing staff by 25%.

 (Privately–held outpatient dialysis service provider)

Senior Vice President & Chief Financial Officer – 2006 to 2007

Brought on board by one of the original investors of Pathology Partners, Inc. (below) and challenged to complete the two ongoing acquisitions and related equity and debt financings; to improve the accuracy, timing, and interpretation of the company's financial statements; to build a technology group, and to move the corporate headquarters to Dallas. Reported to the CEO. Led a 5-person team and managed 40 indirect reports.

Completed the July ’06 acquisition by identifying $1.2 million in post-acquisition synergies to offset target’s over-stated historical financials; selected a new lead bank; and negotiated a $70 million credit facility with a 100% balloon, 5.0 total leverage ratio and 1.20% fixed charge coverage ratio that generated an additional $20 million debt capacity; eliminated $8 million in annual debt amortization; and reduced annual interest costs by more than $200,000.

Designed the company's first complete and accurate financial model to proactively identify upcoming covenant and cash flow problems, optimize covenant calculations, avoid default, and maintain solvency, providing the financial structure to support revenue growth from $25 million to $90 million.

(n/k/a Caris Diagnostics, a privately–held anatomic pathology laboratory)

Senior Vice President & Chief Financial Officer – 2001 to 2005

Selected by the CEO to lead the turnaround of this cash-strapped entity. Managed a 4-person team and 60 indirect reports in raising six rounds of debt financing and two rounds of equity financing, identifying and driving key performance indicators, rationalizing current costs, executing the new business model, and positioning the organization as financially credible to the credit community.

Halted a 3-year history of losses and negative equity, growing revenue from $5 million to $55 million and generating more than 6X total investor return and 40% IRR within four years.  Sold the company to Caris, Ltd. in May, 2005.

(U.S. holding company for Dynacare, Inc., the nation’s 3rd largest clinical laboratory testing company)

Chief Financial Officer, US Operations – 2000 to 2001

Director of Finance, US Operations – 1998 to 2000

Recruited by the COO and CFO and challenged to partner with the US and Canadian management teams to drive domestic business growth and allow investors to exit. Managed 12-15 direct reports and 50+ indirect reports in providing accurate, timely, and meaningfully interpreted financial statements, budgets, and forecasts. Partnered with local finance directors and billing managers to optimize revenue cycle performance and directed US operations audits. Led the post–acquisition integration strategies following four US acquisitions.

Provided the financial leadership and improved accuracy of financial statement content that directly contributed to the growth of the business from $125 million to $350 million in a little more than three years, facilitated the company going public, and positioned it for profitable sale.

(One of the world's largest clinical laboratories)

Regional Director of Finance – 1995 to 1996

Hired specifically to partner with the Regional Director to drive revenue growth and generate cost savings. Led a 4-person team and 80 indirect reports in creating timely, accurate financial statements, budgets, and forecasts for the Dallas region; managed the billing/reimbursement and purchasing functions.

Transformed the worst-rated billing department in the company (according to KPMG) and turned it into the best-rated within the first year, reducing and sustaining annual A/R write–offs by $4.5 million.

Mentored and coached the Billing Manager who won the President’s Award, the company’s most prestigious performance award, for the successful billing department turnaround that pioneered electronic filings yielding a $300,000 costs savings.

(The 127th fastest-growing private company in America)

Chief Financial Officer – 1993 to 1994

Controller – 1992 to 1993

Hired to manage all financial affairs for a private start-up and retained by OSG post-merger. Led a 3-person team in all financial operations and debt financing functions.

Earned 1991 and 1989 company “VIP” awards for combining financial analysis with strategic vision and cost savings.  VIP awards given annually to top two or three performers, by function.

Managed engagements in positions of increasing responsibility.  Clients included SEC (American Airlines, DSC Communications) and non-SEC companies.

Worldwide Clinical Trials is a privately-owned full-service global CRO (clinical research organization) that applies deep therapeutic experience to help pharmaceutical and bio-tech customers achieve their drug development goals.  With operations in over 30 countries, WCT serves most of the world's leading biopharmaceutical companies.